Abstract:OBJECTIVES: Cell-free DNA based non-invasive prenatal testing (NIPT) has been shown with closeto-diagnosis sensitivity and specificity in detecting fetal T21, T18, and T13. Future development of this technology focuses on detection of other chromosomal aneuploidies, and more importantly chromosome copy number variants (CNVs) and single-gene mutations. Validation studies were carried out to demonstrate the feasibility of detecting CNVs and single-gene disease by exploiting the cell-free DNA testing strategy and existing NIPT platforms. METHOD: For testing CNVs, 35 plasma samples with known fetal CNVs (>10 Mb in size) were recruited, together with 1077 plasma samples with normal fetal karyotypes as the control. The samples were blindly tested using the routine NIPT testing pipelines adopted at the clinical laboratories of BGI, and analyzed with the proprietary FCAPS protocol. Results were compared to the karyotyping results to calculate the sensitivity and specificity of the NIPT test. For testing single-gene disease, we developed a unique haplotype-assisted approach which was validated in a Maple Syrup Urine Disease (MSUD) case. In a trio family (father, mother in early pregnancy, and proband), targeted sequencing (180X) of the known genes causing MSUD was used to identify the disease causative mutations in the proband child and parents. At 13 gestational weeks, maternal plasma DNA and genomic DNA of the trio family were tested with a customized array at the sequencing depth of 40X and 20X respectively to retrieve the SNPs information for the purpose of parental haplotypes deduction. Linkage analysis and Hidden Markov Model were then used to construct the fetal genotype and haplotype flanking the MSUD mutation region. RESULTS: For CNV detection, with on average 4–5 M reads per sample and the existing NIPT platforms, we were able to use the FCAPS analytic protocol to identify 32 positive samples in total of 35, and generated 6 false positive cases, leading to overall sensitivity and specificity of 91.4% and 99.4% respectively. False positive rate and false negative rate of the test were 0.56% and 0.28% respectively. We also showed that with an increased sequencing depth, the detection power of the test can be further improved. In the MUSD case, deep targeted sequencing in the trio family identified that the proband child carries a missense mutation and a large deletion on BCKDHA gene, which were inherited from the mother and father respectively. With the SNP markers of the proband and parents, parental haplotype of chromosome 19 in 6148 loci were recovered. After fetal haplotype construction, the same alleles as that of the proband in the causative gene BCKDHA were inherited to the fetus, indicating that the fetus is a MSUD patient. This result was later confirmed by invasive diagnosis, and led to a well-informed decision after post-test counselling. CONCLUSIONS: We demonstrate the successful application of NIPT in detection of CNVs larger than 10 Mb without changing much to the current pipelines of aneuploidy detection. It has the potential to be integrated into the current NIPT test and offer extra benefits to the clinical service. The haplotype-assisted approach we developed requires minimum genetic information to accurately predict fetal condition. It has the clinical potential for noninvasive prenatal diagnosis of single gene disease for family with a proband child and seeks a second healthy child.

Targeted Next‑generation Sequencing for Research and Diagnostics in Congenital Heart Disease, and Cleft Lip And/or Palate.

Noninvasive detection of chromosomal CNV and single gene disease by massively parallel sequencing of cfDNA

A Targeted, Next-Generation Genetic Sequencing Study on Tetralogy of Fallot, Combined With Cleft Lip and Palate.

Detection of Copy Number Variants by Next-Generation Sequencing in Fetuses with Congenital Heart Disease

Chromosome Microarray Testing for Patients with Congenital Heart Defects Reveals Novel Disease Causing Loci and High Diagnostic Yield

Identification Of Sequence Variants In Genetic Disease-Causing Genes Using Targeted Next-Generation Sequencing

Genetic characterisation of 22q11.2 variations and prevalence in patients with congenital heart disease

Copy Number Variant Analysis for Syndromic Congenital Heart Disease in the Chinese Population.

A Modified Multiplex Ligation-Dependent Probe Amplification Method for the Detection of 22q11.2 Copy Number Variations in Patients with Congenital Heart Disease.

Analysis of Pathogenic Variants in 605 Chinese Children with Non-Syndromic Cardiac Conotruncal Defects Based on Targeted Sequencing.

[Analysis of Single-Nucleotide Polymorphism of Sonic Hedgehog Signaling Pathway in Non-Syndromic Cleft Lip And/or Palate in the Chinese Population].

Microdeletion and microduplication analysis of chinese conotruncal defects patients with targeted array comparative genomic hybridization.

The Clinical Utility of Genetic Technologies in Prenatally Diagnosed Cleft Lip and or Palate – a Cohort Study

Prevalence of 22q11.2 Deletion and Genetic Characterization in Chinese Patients with Congenital Heart Disease

Diagnosis of 22q11 Deletion and Duplication in Congenital Heart Disease by Multiplex Ligation-Dependent Probe Amplification

Genetic Analysis of Rare Coding Mutations of CELSR1-3 in Congenital Heart and Neural Tube Defects in Chinese People.

EP06.06: Analysis of Copy Number Variations in Fetal Conotruncal Heart Defects Using Low‐coverage Whole Genome Sequencing

A Pilot Study of Multiplex Ligation-Dependent Probe Amplification Evaluation of Copy Number Variations in Romanian Children with Congenital Heart Defects

Prenatal detection of novel compound heterozygous variants of the PLD1 gene in a fetus with congenital heart disease

Genetic aetiology distribution of 398 foetuses with congenital heart disease in the prenatal setting

Genetic Screening of Targeted Region on the Chromosome 22q11.2 in Patients with Microtia and Congenital Heart Defect